Phase 3 Clinical Trials With Primary Completion Dates in January 2021
This is a list of Phase 3 trials with primary completion dates in January 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AMRN | Amarin Corporation plc | 2021-01-01 | Phase 3 | NCT04460651 | PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial |
| ENDP | Endo International plc | 2021-01-01 | Phase 3 | NCT04170296 | Real World CCH Study in Adult Females With Cellulite |
| FGEN | FibroGen, Inc. | 2021-01-01 | Phase 3 | NCT04410198 | Study of Roxadustat Conversion in Subjects Receiving Stable ESA or as Initial Anemia Treatment in Chronic Dialysis Patients |
| IPIX | Innovation Pharmaceuticals Inc. | 2021-01-01 | Phase 3 | NCT02525939 | Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS |
| MEDP | Medpace Holdings, Inc. | 2021-01-01 | Phase 3 | NCT02525939 | Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS |
| NVAX | Novavax, Inc. | 2021-01-01 | Phase 3 | NCT04583995 | A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom |
| OTLK | Outlook Therapeutics, Inc. | 2021-01-01 | Phase 3 | NCT04516278 | A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders |